Tom Henderson
- Ann Arbor-based ONL Therapeutics Inc., a pharmaceutical company developing therapies for preserving sight for those with a range of retinal diseases, announced Tuesday morning that it has been awarded a commercialization readiness grant of $1 million from the National Eye Institute to continue advancement of ONL1204, the company's lead drug candidate. The drug is designed to protect retinal cells from damage in a range of diseases and conditions, including detached retinas. Death of these
↧